<pp class="qlvzqav"></pp>

尊龙网址登录官网

Be the most trusted biotech company

2024-04-17

IND Application for the Clinical Trial of Novel Anti-TIGIT Fc Fusion Protein HLX53 in Combination with HANSIZHUANG Plus HANBEITAI for the First-Line Treatment of Locally Advanced or Metastatic Hepatocellular Carcinoma Patients Approved by NMPA
2024-04-17

Henlius Releases 2023 ESG Report Pursuing Sustainable Development with Patient-centricity
2024-04-10

Results of Exploratory Biomarker Analysis of Pivotal Clinical Trial ASTRUM-005 of Serplulimab Initially Released at AACR 2024
2024-04-08

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
2024-03-21

Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved
2024-03-20

Henlius’ Trastuzumab Approved in Brazil, a Semi-Exclusive License Area, in Latin America
2024-03-15

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ ADC Candidate HLX42
2024-03-13

Henlius Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Serplulimab in ES-SCLC
2024-03-12

The IND Application of Henlius’ Novel Anti-GARP/TGF-β1 mAb HLX6018 Approved by NMPA

1
...
5
6
7
8
9
10